Abstract
Hidradenitis suppurativa (HS) or acne inversa is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicles that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body, most commonly the axillae, inguinal, and anogenital regions [1]. The disease affects mainly young adults with a female predominance (female to male ratio 2.4–3.3:1). Among the various populations and skin types, prevalence and incidence often differ, but there are no differences in major clinical characteristics. Spontaneous resolution of the disease is rare. Medical treatment targets the inflammatory response, and surgical intervention reduces the burden of the disease offering an overall better outcome. In addition, lifestyle modifications like smoking cessation and weight loss play an important role in improving the prognosis of HS. In recent studies, patients with hidradenitis suppurativa, blistering diseases, leg ulcers, psoriasis, and eczemas had the highest risk for reduction of health-related quality of life among all other non-tumor dermatological conditions [2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–44.
Balieva F, Kupfer J, Lien L, et al. The burden of common skin diseases assessed with the EQ5D™: a European multicentre study in 13 countries. Br J Dermatol. 2017;176:1170–8.
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.
Albares MP, Belinchón I, Ramos JM, et al. Estudio epidemiológico de la patología cutánea en la población inmigrante de Alicante. Actas Dermosifiliogr. 2012;103:214–22.
Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412–9.
Garg A, Kirby JS, Lavian J et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis Suppurativa in the United States. JAMA Dermatol. 2017;153:760–4.
Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97–103.
Garg A, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77:118–22.
Vlassova N, Kuhn D, Okoye GA. Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis. Acta Derm Venereol. 2015;95:990–1.
von Laffert M, Stadie V, Wohlrab J, et al. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367–71.
Ingram JR. The genetics of hidradenitis suppurativa. Dermatol Clin. 2016;34:23–8.
Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(suppl 1):S8–S11.
Chen S, Mattei P, You J, et al. γ-Secretase mutation in an African American family with hidradenitis suppurativa. JAMA Dermatol. 2015;151:668–70.
Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17:455–72.
Karagiannidis I, Nikolakis G, Zouboulis CC. Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin. 2016;34:45–9.
Nikolakis G, Join-Lambert O, Karagiannidis I, et al. Bacteriology of hidradenitis suppurativa/acne inversa: a review. J Am Acad Dermatol. 2015;73(suppl 1):S12–8.
Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–64.
Peters NJ, Kapoor R. Gluteal and perianal hidradenitis suppurativa associated with tuberculosis. Indian J Surg. 2012;74:194–5.
Patnaik S, Mohanty I, Panda P, et al. Disseminated mycobacterium chelonae infection: complicating a case of hidradenitis suppurativa. Ind Dermatol Online J. 2013;4:336–9.
Fabbrocini G, Ruocco E, De Vita V, et al. Squamous cell carcinoma arising in long-standing hidradenitis suppurativa: an overlooked facet of the immunocompromised district. Clin Dermatol. 2017;35:225–7.
Zouboulis CC, del Marmol V, Mrowietz U, et al. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184–90.
Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546–9.
Zouboulis CC, Tzellos T, Kyrgidis A et al. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br J Dermatol. 2017; 177:1401–9.
Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk RK, Roenigk Jr HH, editors. Dermatologic surgery. Principles and practice. 2nd ed. New York: Marcel Dekker; 1996. p. 623–45.
Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173:464–70.
Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173:1142–55.
Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinology. 2010;2:9–16.
Egeberg A, Jemec GBE, Kimball AB, et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J Invest Dermatol. 2017;137:1060–4.
Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol. 2017;18:555–62.
Zouboulis CC, Desai N, Emtestam L, et al. Partial actualization of the European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Exp Dermatol. 2016;25(suppl 2):13.
Bartalesi F, Bartoloni A, Bisoffi Z, et al. The emerging problem of biological treatment in migrant and travelling populations: it is time to extend guidelines for the screening of infectious diseases. Ann Rheum Dis. 2014;73:794–6.
Janse I, Bieniek A, Horváth B, et al. Surgical procedures in hidradenitis suppurativa. Dermatol Clin. 2016;34:97–109.
Kromann CB, Ibler KS, Kristiansen VB, et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553–7.
Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171:819–24.
Danby FW. Diet in the prevention of hidradenitis suppurativa (acne inversa). J Am Acad Dermatol. 2015;73(suppl 1):S52–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Zouboulis, C.C., Goyal, M. (2018). Hidradenitis Suppurativa. In: Orfanos, C., Zouboulis, C., Assaf, C. (eds) Pigmented Ethnic Skin and Imported Dermatoses. Springer, Cham. https://doi.org/10.1007/978-3-319-69422-1_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-69422-1_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-69421-4
Online ISBN: 978-3-319-69422-1
eBook Packages: MedicineMedicine (R0)